Eagle Pharmaceuticals, Inc. EGRX

EGRX Company Overview

Eagle Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company focused on developing and commercializing injectable and hospital-administered medicines, primarily in oncology, critical care, and central nervous system-related therapeutic areas. The company operates within the branded specialty pharmaceutical and pharmaceutical licensing industries, with a strategy centered on improving existing medicines through differentiated formulations, delivery methods, and lifecycle management. Eagle has historically generated revenue through product sales, royalty arrangements, licensing agreements, and collaborative commercialization partnerships.

The company’s primary revenue drivers have included products associated with rapid infusion oncology therapies, supportive care medicines, and hospital-based injectables. Eagle became known for developing bendamustine formulations marketed under products such as BENDEKA and BELRAPZO through licensing and commercialization partnerships. The company has also expanded into neuroscience and emergency care through acquisitions and product licensing arrangements. Founded in 2007 and headquartered in Woodcliff Lake, New Jersey, Eagle evolved from a reformulation-focused pharmaceutical developer into a broader specialty pharmaceutical platform with both commercial and development-stage assets.